212 related articles for article (PubMed ID: 31249943)
1. Evaluation of the DOAC-Stop® Procedure to Overcome the Effect of DOACs on Several Thrombophilia Screening Tests.
Favresse J; Lardinois B; Sabor L; Devalet B; Vandepapeliere J; Braibant M; Lessire S; Chatelain B; Jacqmin H; Douxfils J; Mullier F
TH Open; 2018 Apr; 2(2):e202-e209. PubMed ID: 31249943
[TBL] [Abstract][Full Text] [Related]
2. The effect of DOAC-Stop on lupus anticoagulant testing in plasma samples of venous thromboembolism patients receiving direct oral anticoagulants.
Ząbczyk M; Kopytek M; Natorska J; Undas A
Clin Chem Lab Med; 2019 Aug; 57(9):1374-1381. PubMed ID: 30763261
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of the DOAC-Stop Procedure by LC-MS/MS Assays for Determining the Residual Activity of Dabigatran, Rivaroxaban, and Apixaban.
Slavik L; Jacova J; Friedecky D; Ulehlova J; Tauber Z; Prochazkova J; Hlusi A; Palova M
Clin Appl Thromb Hemost; 2019; 25():1076029619872556. PubMed ID: 31523979
[TBL] [Abstract][Full Text] [Related]
4. Simple method for removing DOACs from plasma samples.
Exner T; Michalopoulos N; Pearce J; Xavier R; Ahuja M
Thromb Res; 2018 Mar; 163():117-122. PubMed ID: 29407622
[TBL] [Abstract][Full Text] [Related]
5. Unveiling the complex effects of direct oral anticoagulants on dilute Russell's viper venom time assays.
Hillarp A; Strandberg K; Gustafsson KM; Lindahl TL
J Thromb Haemost; 2020 Aug; 18(8):1866-1873. PubMed ID: 32294291
[TBL] [Abstract][Full Text] [Related]
6. Laboratory testing for lupus anticoagulant (LA) in patients taking direct oral anticoagulants (DOACs): potential for false positives and false negatives.
Favaloro EJ; Mohammed S; Curnow J; Pasalic L
Pathology; 2019 Apr; 51(3):292-300. PubMed ID: 30665674
[TBL] [Abstract][Full Text] [Related]
7. Potential usefulness of activated charcoal (DOAC remove®) for dRVVT testing in patients receiving Direct Oral AntiCoagulants.
Jourdi G; Delrue M; Stepanian A; Valaize J; Foulon-Pinto G; Demagny J; Duchemin J; Nedelec-Gac F; Darnige L; Curis E; Delavenne X; Gaussem P; Siguret V; Gouin-Thibault I
Thromb Res; 2019 Dec; 184():86-91. PubMed ID: 31710863
[TBL] [Abstract][Full Text] [Related]
8. The effect of DOACs on laboratory tests and their removal by activated carbon to limit interference in functional assays.
Exner T; Rigano J; Favaloro EJ
Int J Lab Hematol; 2020 Jun; 42 Suppl 1():41-48. PubMed ID: 32543072
[TBL] [Abstract][Full Text] [Related]
9. Direct oral anticoagulant adsorption: Impact on lupus anticoagulant testing-Review of the literature and evaluation on spiked and patient samples.
De Kesel PM; Devreese KMJ
J Thromb Haemost; 2020 Aug; 18(8):2003-2017. PubMed ID: 32400112
[TBL] [Abstract][Full Text] [Related]
10. DOAC-Remove abolishes the effect of direct oral anticoagulants on activated protein C resistance testing in real-life venous thromboembolism patients.
Kopytek M; Ząbczyk M; Malinowski KP; Undas A; Natorska J
Clin Chem Lab Med; 2020 Feb; 58(3):430-437. PubMed ID: 31539350
[TBL] [Abstract][Full Text] [Related]
11. Influence of DOAC Stop on coagulation assays in samples from patients on rivaroxaban or apixaban.
Platton S; Hunt C
Int J Lab Hematol; 2019 Apr; 41(2):227-233. PubMed ID: 30468572
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of DOAC Filter, a new device to remove direct oral anticoagulants from plasma samples.
Sevenet PO; Cucini V; Hervé T; Depasse F; Carlo A; Contant G; Mathieu O
Int J Lab Hematol; 2020 Oct; 42(5):636-642. PubMed ID: 32567799
[TBL] [Abstract][Full Text] [Related]
13. Screening test for direct oral anticoagulants with the dilute Russell viper venom time.
Pratt J; Crispin P
Eur J Haematol; 2018 Jun; 100(6):567-574. PubMed ID: 29486103
[TBL] [Abstract][Full Text] [Related]
14. Effects of direct oral anticoagulants on lupus anticoagulant assays in a real-life setting.
Antovic A; Norberg EM; Berndtsson M; Rasmuson A; Malmström RE; Skeppholm M; Antovic J
Thromb Haemost; 2017 Aug; 117(9):1700-1704. PubMed ID: 28640321
[TBL] [Abstract][Full Text] [Related]
15. Clotting test results correlate better with DOAC concentrations when expressed as a "Correction Ratio"; results before/after extraction with the DOAC Stop reagent.
Exner T; Favresse J; Lessire S; Douxfils J; Mullier F
Thromb Res; 2019 Jul; 179():69-72. PubMed ID: 31096112
[TBL] [Abstract][Full Text] [Related]
16. An optimized dRVVT-based assay to estimate the intensity of anticoagulation in patients treated with direct oral anticoagulants.
Sennesael AL; Exner T; Chatelain B; Lessire S; Larock AS; Vancraeynest C; Pochet L; Dogné JM; Spinewine A; Mullier F; Douxfils J
Thromb Res; 2017 Sep; 157():29-37. PubMed ID: 28686914
[TBL] [Abstract][Full Text] [Related]
17. Comparison of the effect of the anti-Xa direct oral anticoagulants apixaban, edoxaban, and rivaroxaban on coagulation assays.
Gosselin R; Grant RP; Adcock DM
Int J Lab Hematol; 2016 Oct; 38(5):505-13. PubMed ID: 27265752
[TBL] [Abstract][Full Text] [Related]
18. DOAC-Stop in lupus anticoagulant testing: Direct oral anticoagulant interference removed in most samples.
Baker SA; Jin J; Pfaffroth C; Vu T; Zehnder JL
Res Pract Thromb Haemost; 2021 Feb; 5(2):314-325. PubMed ID: 33733031
[TBL] [Abstract][Full Text] [Related]
19. Dilute Russell's viper venom time reagents in lupus anticoagulant testing: a well-considered choice.
Depreter B; Devreese KM
Clin Chem Lab Med; 2017 Jan; 55(1):91-101. PubMed ID: 27331311
[TBL] [Abstract][Full Text] [Related]
20. Comprehensive review of the impact of direct oral anticoagulants on thrombophilia diagnostic tests: Practical recommendations for the laboratory.
Siriez R; Dogné JM; Gosselin R; Laloy J; Mullier F; Douxfils J
Int J Lab Hematol; 2021 Feb; 43(1):7-20. PubMed ID: 32946681
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
